Population pharmacokinetics and pharmacodynamics of hydroxyurea in sickle cell anemia patients a basis for optimizing the dosing regimen

摘要

BackgroundHydroxyurea (HU) is the first approved pharmacological treatment of sickle cell anemia (SCA). The objectives of this study were to develop population pharmacokinetic(PK)-pharmacodynamic(PD) models for HU in order to characterize the exposure-efficacy relationships and their variability, compare two dosing regimens by simulations and develop some recommendations for monitoring the treatment.